Articles from SAGA Diagnostics

SAGA Diagnostics, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, today announced that the company and key collaborators will present data from three abstracts at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, taking place May 29 to June 2 in Chicago.

SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for early molecular residual disease (MRD) detection, today announced that the company and its collaborators will present data from two abstracts at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22 in San Diego, California. These abstracts showcase the ultrasensitive structural variant (SV)-based detection of circulating tumor DNA (ctDNA) in metastatic breast cancer (mBC) and high-grade serous ovarian cancer (HGSOC).

SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for ultrasensitive and early molecular residual disease (MRD) detection, today announced the launch of its ultrasensitive Pathlight MRD diagnostic test for patients with colorectal cancer (CRC). This expands the clinical application of Pathlight following its successful commercial launch in early-stage breast cancer last year.

SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for ultrasensitive and early molecular residual disease (MRD) detection, joins collaborators from the Karolinska Institutet to present new clinical data showcasing the ultrasensitive detection of ctDNA in colorectal cancer (CRC) using Pathlight at the 2026 American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, January 8-10 in San Francisco, CA.

SAGA Diagnostics®, a pioneer in blood-based cancer detection and precision medicine redefining the standard for ultra-sensitive and early molecular residual disease (MRD) detection, joined collaborating investigators at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, TX this week to present data from two trials evaluating neoadjuvant therapy outcomes in triple-negative breast cancer (TNBC).

SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for ultra-sensitive and early molecular residual disease (MRD) detection, will present five posters—three new studies and two trials in progress—at the 2025 San Antonio Breast Cancer Symposium (SABCS), December 9-12, 2025 in San Antonio, TX.

SAGA Diagnostics, a pioneer in blood-based cancer testing redefining the standard for ultra-sensitive molecular residual disease (MRD) detection, today announced that SAGA will present at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. The conference is one of the sector’s most influential investor events, bringing together leading private and public healthcare companies with institutional investors, strategic partners, and sector analysts.

SAGA Diagnostics, a pioneer in blood-based cancer testing redefining the standard for ultra-sensitive molecular residual disease (MRD) detection, today announced that Palmetto GBA’s Molecular Diagnostic Services Program (MolDX) issued a positive coverage decision for the Pathlight MRD test. Pathlight is covered for Medicare beneficiaries for recurrence monitoring in the surveillance setting for up to six years in patients with stage II-III breast cancer, including all subtypes: HR+/HER2-, HER2+ and TNBC.

SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for ultra-sensitive and early molecular residual disease (MRD) detection, today announced the U.S. commercial launch of its Pathlight test for the detection of residual disease and recurrence at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, May 30 - June 3.